AB Science Advances Masitinib Clinical Development
Biopharmaceutical company AB Science is focusing on the development of masitinib, particularly for rare diseases and oncology. The company actively reports on progress in its clinical studies.
Biopharmaceutical company AB Science is advancing the clinical development of its drug candidate, masitinib, across multiple therapeutic areas, with a focus on rare diseases and oncology.
The company reports on the progress of its ongoing clinical trials, which include investigations into masitinib for progressive forms of multiple sclerosis, amyotrophic lateral sclerosis (ALS), sickle cell disease, and Alzheimer's disease. Additionally, AB Science is exploring the potential of AB8939 in the treatment of acute myeloid leukemia (AML).
AB Science is committed to developing therapies that address significant unmet medical needs. Its research strategy centers on leveraging the therapeutic potential of its drug candidates across diverse medical conditions.
The company provides updates on its clinical study activities, aiming to keep stakeholders informed about the development pipeline.